191 related articles for article (PubMed ID: 21715107)
1. A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence.
Bisaga A; Sullivan MA; Cheng WY; Carpenter KM; Mariani JJ; Levin FR; Raby WN; Nunes EV
Drug Alcohol Depend; 2011 Dec; 119(1-2):e23-9. PubMed ID: 21715107
[TBL] [Abstract][Full Text] [Related]
2. A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence.
Bisaga A; Sullivan MA; Glass A; Mishlen K; Carpenter KM; Mariani JJ; Levin FR; Nunes EV
J Subst Abuse Treat; 2014; 46(5):546-52. PubMed ID: 24560438
[TBL] [Abstract][Full Text] [Related]
3. Adjunctive memantine for opioid use disorder treatment: A systematic review.
Elias AM; Pepin MJ; Brown JN
J Subst Abuse Treat; 2019 Dec; 107():38-43. PubMed ID: 31757263
[TBL] [Abstract][Full Text] [Related]
4. Problem drinking and low-dose naltrexone-assisted opioid detoxification.
Mannelli P; Peindl K; Patkar AA; Wu LT; Tharwani HM; Gorelick DA
J Stud Alcohol Drugs; 2011 May; 72(3):507-13. PubMed ID: 21513688
[TBL] [Abstract][Full Text] [Related]
5. Lofexidine in Combination With Oral Naltrexone for Opioid Use Disorder Relapse Prevention: A Pilot Randomized, Double-Blind, Placebo-Controlled Study.
Hermes G; Hyman SM; Fogelman N; Kosten TR; Sinha R
Am J Addict; 2019 Nov; 28(6):480-488. PubMed ID: 31448846
[TBL] [Abstract][Full Text] [Related]
6. The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans.
Bisaga A; Comer SD; Ward AS; Popik P; Kleber HD; Fischman MW
Psychopharmacology (Berl); 2001 Aug; 157(1):1-10. PubMed ID: 11512037
[TBL] [Abstract][Full Text] [Related]
7. The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone.
Bisaga A; Sullivan MA; Glass A; Mishlen K; Pavlicova M; Haney M; Raby WN; Levin FR; Carpenter KM; Mariani JJ; Nunes EV
Drug Alcohol Depend; 2015 Sep; 154():38-45. PubMed ID: 26187456
[TBL] [Abstract][Full Text] [Related]
8. [A double-blind randomized placebo-controlled study of the efficacy of the combined treatment with naltrexone and guanfacine for relapse prevention in opiate dependence].
Krupitsky EM; Blokhina EA; Zvartau EE; Verbitskaya VE; Bushara EM; Tiurina AA; Palatkin VY; Yaroslavtseva TS; Burakov AM; Masalov DV; Romanova TN; Grininko AY; Sinha R; Kosten T
Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(10):39-46. PubMed ID: 26525620
[TBL] [Abstract][Full Text] [Related]
9. The combination very low-dose naltrexone-clonidine in the management of opioid withdrawal.
Mannelli P; Peindl K; Wu LT; Patkar AA; Gorelick DA
Am J Drug Alcohol Abuse; 2012 May; 38(3):200-5. PubMed ID: 22233189
[TBL] [Abstract][Full Text] [Related]
10. A double-blind, double-dummy, randomized controlled study of memantine versus buprenorphine in naloxone-precipitated acute withdrawal in heroin addicts.
Jain K; Jain R; Dhawan A
J Opioid Manag; 2011; 7(1):11-20. PubMed ID: 21434580
[TBL] [Abstract][Full Text] [Related]
11. Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings.
Sinha R; Kimmerling A; Doebrick C; Kosten TR
Psychopharmacology (Berl); 2007 Mar; 190(4):569-74. PubMed ID: 17136399
[TBL] [Abstract][Full Text] [Related]
12. The NMDA receptor channel blocker memantine and opioid receptor antagonist naltrexone inhibit the saccharin deprivation effect in rats.
Zakharova E; Malyshkin A; Kashkin V; Neznanova O; Sukhotina I; Danysz W; Bespalov A
Behav Pharmacol; 2004 Jul; 15(4):273-8. PubMed ID: 15252277
[TBL] [Abstract][Full Text] [Related]
13. Naltrexone treatment for opioid dependence: does its effectiveness depend on testing the blockade?
Sullivan MA; Bisaga A; Mariani JJ; Glass A; Levin FR; Comer SD; Nunes EV
Drug Alcohol Depend; 2013 Nov; 133(1):80-5. PubMed ID: 23827259
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
Dunn KE; Tompkins DA; Bigelow GE; Strain EC
JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
[TBL] [Abstract][Full Text] [Related]
15. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial.
Comer SD; Sullivan MA; Yu E; Rothenberg JL; Kleber HD; Kampman K; Dackis C; O'Brien CP
Arch Gen Psychiatry; 2006 Feb; 63(2):210-8. PubMed ID: 16461865
[TBL] [Abstract][Full Text] [Related]
16. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
Krupitsky E; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Silverman BL
Lancet; 2011 Apr; 377(9776):1506-13. PubMed ID: 21529928
[TBL] [Abstract][Full Text] [Related]
17. Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial.
Jayaram-Lindström N; Hammarberg A; Beck O; Franck J
Am J Psychiatry; 2008 Nov; 165(11):1442-8. PubMed ID: 18765480
[TBL] [Abstract][Full Text] [Related]
18. Risk-taking propensity as a predictor of induction onto naltrexone treatment for opioid dependence.
Aklin WM; Severtson SG; Umbricht A; Fingerhood M; Bigelow GE; Lejuez CW; Silverman K
J Clin Psychiatry; 2012 Aug; 73(8):e1056-61. PubMed ID: 22967782
[TBL] [Abstract][Full Text] [Related]
19. Naltrexone shortened opioid detoxification with buprenorphine.
Umbricht A; Montoya ID; Hoover DR; Demuth KL; Chiang CT; Preston KL
Drug Alcohol Depend; 1999 Oct; 56(3):181-90. PubMed ID: 10529020
[TBL] [Abstract][Full Text] [Related]
20. Effects of the NMDA receptor antagonist memantine on the expression and development of acute opiate dependence as assessed by withdrawal-potentiated startle and hyperalgesia.
Harris AC; Rothwell PE; Gewirtz JC
Psychopharmacology (Berl); 2008 Mar; 196(4):649-60. PubMed ID: 18026718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
